Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome.
Metz
Kelly Allred
KA
Johnson
Theodore
T
Hershey
Gurjit K Khurana
GK
Lierl
Michelle B
MB
Seidu
Luqman
L
Burns
Karen
K
Assa'ad
Amal
A
D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004155:Diphenhydramine / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008775:Methylprednisolone / Q000627:therapeutic use; D011292:Premedication; D011899:Ranitidine / Q000627:therapeutic use; D013577:Syndrome; D016896:Treatment Outcome
D006633:Histamine Antagonists; D007166:Immunosuppressive Agents; D003561:Cytarabine; D011899:Ranitidine; D004155:Diphenhydramine; D008775:Methylprednisolone